Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc.

A recent study reveals that a novel postbiotic supplement, Pet Immune, significantly alleviates itching and enhances skin and ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

On June 26, Arcutis Biotherapeutics Inc. announced that ZORYVE (roflumilast) cream 0.15% received a strong recommendation in ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

President Donald Trump has signed House Resolution 1 (H.R. 1), the final version of which does not impose a moratorium on state legislation governing the use of AI. The bill does, however, restore the ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...